P03 · Retatrutide

Also known as: LY3437943, triple agonist

Core | Investigational

INDICATION

Sponsor (Lilly) reported positive TRIUMPH Phase 3 toplines (Jul 2026) and plans BLA Q1 2027 — filing ≠ approval.

ADMINISTRATION

SC

DOSAGE

Label N/A; Phase 2 weekly 1–12 mg class arms; course gray vials — refuse [Course-claimed]

BEST DATA

Phase 2 obesity (Jastreboff 2023 NEJM): up to ~24% mean WL at 48 wk in 12 mg group vs ~2% PBO · PMID 37366315 · NCT04881760. Primary endpoint 24 wk % weight change; GI AEs dose-related; HR ↑ noted.

EXPECTED OUTCOMES

Large mean weight reductions in Phase 2 obesity population.; Glycemic improvements observed in development program (details in papers/toplines).

SAFETY / CAUTION

Caution: GI AEs similar to incretin class; dose-dependent in Phase 2.; Heart-rate increases peaked mid-trial then declined (Phase 2 report).

Regulatory snapshot (FDA-focused): compounded / investigational